参考文献 [1] Turgeon RD, Koshman SL, Dong Y,et al. P2Y12 inhibitor adherence trajectories in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prognostic implications. Eur Heart J. 2022 Jun 21;43(24):2303...
2024年3月，《JAMA Network Open》杂志发表一项研究《P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial》证实了在新一代DES植入后，可以对DAPT的持续时间进行个体化调整，并提供了减少PCI后出血并发症的潜在策略，同时保持了对心...
1033例在冠脉造影前、591例在导管室分别接受了P2Y12抑制剂治疗;两组氯吡格雷使用比例为75%、51.8%,使用替格瑞洛的比例分别为19.5%和40.6%,使用普拉格雷的比例分别为5.5%和7.6%。 来源:Almendro-Delia M, Hernández-Meneses B, Padilla-Rodríguez G, et al...
声明还特别指出,主要根据我国王拥军教授领衔开展的CHANCE-2研究结果,在轻型缺血性中风或短暂脑缺血发作的东亚患者中,基因检测对于识别CYP2C19功能缺失等位基因携带者可能是有益的,该类患者应考虑用替格瑞洛和阿司匹林而不是氯吡格雷和阿司匹林治疗90天。 来源:CYP2C19Genetic Testing for Oral P2Y12Inhibitor Therapy: A S...
5. Joo-Yong Hahn. P2Y12 Inhibitor Monotherapy versus Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention The SMART-CHOICE randomized, open-label, noninferiority trial. ACC 2019, 2019.3.18 6. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the man...
有几种药物与血小板上的P2Y12受体相互作用,从而降低血小板功能。一些已经被用作抗血栓药物,另一些正在开发中,这些药物,统称为P2Y12受体抑制剂(P2Y12 receptor inhibitor)或者P2Y12受体拮抗剂(P1Y12receptor antagonist)。 P2Y12受体抑制剂作对细胞信号传导造成的影响 ...
P2Y12inhibitor monotherapy after PCI. Generalizing the results of studies of P2Y12inhibitor monotherapy requires a thorough understanding of their design, populations, interventions, comparators and results. In this Review, we provide an up-to-date overview on the use of P2Y12inhibitor monotherapy ...
来源:CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association. Circulation, 20 June 2024 医脉通是专业的在线医生平台,“感知世界医学脉搏,助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通...
来源:CYP2C19Genetic Testing for Oral P2Y12Inhibitor Therapy: A Scientific Statement From the American Heart Association. Circulation, 20 June 2024 转
For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 year